Researchers find potential one-two punch against triple-negative breast cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 00:15 ET (22-Jun-2026 04:15 GMT/UTC)
Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme – RNase H2 – that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast cancer therapies work by causing replication stress, these results suggest RNase H2 is a promising treatment target.
Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment of breast cancer.
A genomic study of the largest pediatric and adult aplastic anemia cohort genetically profiled to date, finds that protective mutations arise as independent events in different stem cells years before diagnosis.
UC San Diego biologists have identified a way to reinvigorate immune system cells, which can become exhausted after fighting disease. They found that protein recycling malfunctions after a cell burns out. Restoring a proper recycling system allows T cells to regain their cancer-fighting functions.